title: [Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 1. Single-dose administration].
abstract: Comparison of the Pharmacokinetic Profiles of a Quick and a Sustained Release Bezafibrate Formulation/1st Communication: Single-dose application The hypolipaemic agent bezafibrate (CAS 41859-67-0) is available as immediate and sustained release formulation. The pharmacokinetic profile of an immediate release 300 mg dragee (A) was compared in a two-way cross-over design to that of a 400 mg sustained release dragee (B). Neglecting the dose difference, the AUEC of A (28.8 micrograms/ml.h) was equal to that of B (27.6 micrograms/ml.h), whereas the bioavailability of A appeared to be higher than that of B when AUEC was corrected for dose (AUEC ratio = 137%). Regarding Cmax and tmax, both formulations exhibited the expected differences.
authors: McKnight Laboratories GmbH, Hamburg.
authors: B
authors: B
authors: Vens-Cappell
authors: C
authors: C
authors: Hilgenstock
authors: M
authors: M
authors: Gellert
authors: K
authors: K
authors: Kühle
authors: I
authors: I
authors: Reifferscheid
authors: P
authors: P
authors: Winckler
authors: K G
authors: KG
authors: Bührens
mesh_terms: D000328:Adult; D001629:Bezafibrate / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001682:Biological Availability; D003692:Delayed-Action Preparations; D004562:Electrocardiography; D006801:Humans; D008297:Male; D013607:Tablets
chemical_list: D003692:Delayed-Action Preparations; D013607:Tablets; D001629:Bezafibrate
vernacular_title: Vergleich der Pharmakokinetik einer schnellfreisetzenden Bezafibrat-Formulierung mit einer Retard-Formulierung. 1. Mitteilung: Single-dose-Applikation.